drugset / Trial / NCT01785472

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

NCT01785472

Phase 3 Completed 1438 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension

Timeline

Start
2013-04
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject LCZ696 Unknown 200 mg
Subject LCZ696 Unknown 400 mg
Subject Olmesartan Other / unclassified 20 mg